Schizophrenia Clinical Trial
Official title:
A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia
Status | Completed |
Enrollment | 106 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60), according to DSM-?-TR (M.I.N.I.KID will be used as backup) - Male and female patients aged 13-17 years (between IC and end of dosing) - Patients with a PANSS score of 70 or more [both at start of dosing (Day 1 and at baseline - Patients who, in addition to their legal guardian, provide written informed consent, having understood the details of this study - Inpatient or outpatient status Exclusion Criteria: - Patients who have a diagnosis of any other disease except schizophrenia, according to DSM-IV-TR - Patients who have been compulsorily admitted to hospital - Patients with mental retardation - Patients with thyroid disorder - Patients who have a history of receiving treatment with clozapine, or who have received sufficient doses of two or more kinds of antipsychotic drug for more than four weeks but failed to respond to this treatment - Patients who have received a prohibited concomitant medication or therapy listed in table 6.4-1 after the start of the prohibited concomitant medication timeframe [to be confirmed at start of dosing (Day 1) and at baseline]. - Patients who have a history of receiving treatment with aripiprazole - Patients who fall under a contraindication listed in the ABILIFY package insert - Patients with a serious hepatic, renal, cardiac or hematopoietic disorder - Patients with a history or a complication of organic brain disorder or convulsive disorder such as epilepsy - Patients with diabetes. and patients who fall under any of the following: fasting blood glucose level ?126 mg/dL, non-fasting blood glucose level ?200 mg/dL, HbA1c?6.5% - Patients with a history or a complication of suicide attempt, suicidal thought or self-harm - Patients with a score of ?2(mild) on PART1 evaluation of CGI-SS - Patients with a history or a complication of malignant syndrome, tardive dyskinesia or paralytic ileus - Patients in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition - Patients with a history or a complication of water intoxication - Patients with Parkinson's disease - Pregnant women, parturient women, nursing women, women of childbearing potential who wish to become pregnant during this trial. However, women of childbearing potential who are practicing an appropriate method of contraception and have a negative pregnancy test result are eligible for inclusion in this study. - Patients who have a diagnosis of a substance-related disorder according to DSM-?-TR within the past 3 months - Patients with a positive drug screen (urine) result - Study enrollment is otherwise judged to be inappropriate by the Investigator or Subinvestigator |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Otsuka Pharmaceutical Co., Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive and Negative Syndrome Scale (PANSS) total sore | Change from baseline to final evaluation | baseline, Day 43 | No |
Secondary | PANSS score | Screening, Day1, Day8, Day15, Day22, Day29, Day43 | No | |
Secondary | Clinical Global Impression (CGI) | Day1, Day8, Day15, Day22, Day29, Day43 | No | |
Secondary | Children's Global Assessment Scale (CGAS) | Day1, day43 | No | |
Secondary | Adverse events | up to Day 43 | Yes | |
Secondary | Electrocardiogram | Screening, Day43 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |